Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21609720 | 1.00 | HRH3 (0.60) | HRH3NFE2L2HPGDL3MBTL1ATM | |
| SCHEMBL23163613 | 0.91 | NFE2L2 (0.70) | HRH3NFE2L2HPGDL3MBTL1ATM | |
| SCHEMBL30674634 | 0.83 | HRH3 (0.60) | HRH3NFE2L2HPGDPTGESLTA4H | |
| SCHEMBL30674523 | 0.83 | HRH3 (0.60) | HRH3NFE2L2HPGDPTGESKDM4E | |
| SCHEMBL27981217 | 0.83 | HRH3 (0.60) | HRH3NFE2L2HPGDPTGESLTA4H | |
| SCHEMBL30674533 | 0.83 | HRH3 (0.60) | HRH3NFE2L2HPGDPTGESKDM4E | |
| SCHEMBL22260017 | 0.83 | NFE2L2 (0.84) | HRH3NFE2L2HPGDPTGESTDP1 | |
| SCHEMBL30674529 | 0.83 | HRH3 (0.64) | HRH3NFE2L2HPGDPTGES | |
| SCHEMBL5207816 | 0.82 | HRH3 (0.59) | HRH3NFE2L2HPGDPTGESSMN1; SMN2 | |
| SCHEMBL9346158 | 0.82 | KDM4E (0.47) | HRH3L3MBTL1ATMTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255457-A1 | PROCESS FOR THE REMOVAL AND RETURN OF A CATALYST TO A LIQUID PHASE MEDIUM | PHOSPHONICS LTD (GB) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255457-A1 | PROCESS FOR THE REMOVAL AND RETURN OF A CATALYST TO A LIQUID PHASE MEDIUM | MSR1, NOC2L, GFRA2 | HRH3 625/4885NFE2L2 401/4885HPGD 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.